NCI-led PDS01ADC prostate cancer study presented, PDS Biotechnology (PDSB) issues update

Rhea-AI Filing Summary

PDS Biotechnology Corporation reported that results from a National Cancer Institute-led study of its investigational Interleukin-12 (IL-12) tumor-targeted immunocytokine, PDS01ADC, were presented at a major prostate cancer research conference. The presentation took place at an American Association of Cancer Research special conference in Boston, covering meetings held January 20-22, 2026.

The company issued a press release on January 28, 2026 to share this update, and that release is attached as an exhibit to the filing, providing more detail on the study and its findings.

8-K Event Classification

2 items: 8.01, 9.01

2 items

Item 8.01 Other Events Other

Voluntary disclosure of events the company deems important to shareholders but not covered by other items.

Item 9.01 Financial Statements and Exhibits Exhibits

Financial statements, pro forma financial information, and exhibit attachments filed with this report.

Understanding 8-K Material Events →

false0001472091NASDAQ00014720912026-01-282026-01-28

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, DC 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the

Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): January 28, 2026

PDS BIOTECHNOLOGY CORPORATION

(Exact Name of Registrant as Specified in Charter)

Delaware	001-37568	26-4231384
(State or Other Jurisdiction of Incorporation)	(Commission File Number)	(I.R.S. Employer Identification No.)

303A College Road East, Princeton, NJ 08540

(Address of Principal Executive Offices, and Zip Code)

(800) 208-3343

Registrant’s Telephone Number, Including Area Code

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

☐
Written communication pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐
Pre-commencement communication pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐
Pre-commencement communication pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Common Stock, par value $0.00033 per share	PDSB	The Nasdaq Capital Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. Yes ☐ No ☐

Item 8.01 Other Events.

On January 28, 2026, PDS Biotechnology Corporation (the “Company”) issued a press release announcing that results of a National Cancer Institute-led study of the Company’s investigational Interleukin-12 (IL-12) tumor targeted immunocytokine, PDS01ADC, were presented at the American Association of Cancer Research special conference on prostate cancer research, held in Boston, MA on January 20-22, 2026.

 A copy of the press release is filed herewith as Exhibit 99.1 and incorporated by reference herein.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits.

Exhibit Number		Description
99.1		Press Release Dated January 28, 2026.
104		Cover Page Interactive Data File (embedded within the Inline XBRL Document).

Signature

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

		PDS BIOTECHNOLOGY CORPORATION
	Date:  January 28, 2026	By:	/s/ Frank Bedu-Addo, Ph.D.
		Name: Frank Bedu-Addo, Ph.D.
		Title: President and Chief Executive Officer

FAQ

What did PDSB disclose in its latest 8-K filing?

PDS Biotechnology disclosed that results from a National Cancer Institute-led study of its investigational IL-12 tumor-targeted immunocytokine, PDS01ADC, were presented at an American Association of Cancer Research special prostate cancer conference in Boston held January 20-22, 2026.

What is PDS01ADC in the PDSB 8-K filing?

PDS01ADC is PDS Biotechnology’s investigational Interleukin-12 (IL-12) tumor-targeted immunocytokine. The filing notes that study results involving this candidate were led by the National Cancer Institute and presented at a specialized American Association of Cancer Research prostate cancer conference.

When were the PDS01ADC study results presented?

The study results for PDS Biotechnology’s investigational PDS01ADC were presented at an American Association of Cancer Research special conference on prostate cancer research held in Boston, Massachusetts from January 20 to January 22, 2026, according to the company’s 8-K disclosure.

How did PDS Biotechnology communicate the PDS01ADC study update?

PDS Biotechnology communicated the PDS01ADC study update through a press release dated January 28, 2026. The company attached this release as Exhibit 99.1 to its 8-K, incorporating the announcement and additional study details by reference into the filing.

What role did the National Cancer Institute play in the PDS01ADC study?

The National Cancer Institute led the study involving PDS Biotechnology’s investigational IL-12 tumor-targeted immunocytokine, PDS01ADC. The 8-K highlights that the NCI-directed research produced results significant enough to be presented at a specialized American Association of Cancer Research prostate cancer conference.

Who signed the PDSB 8-K related to the PDS01ADC study?

The 8-K related to the PDS01ADC study was signed on behalf of PDS Biotechnology by Frank Bedu-Addo, Ph.D., the company’s President and Chief Executive Officer, dated January 28, 2026, confirming the company’s authorization of the disclosure.